GlassScriptPhysician profile
Richard W Yemm
NPI 1326498593
$2,552.97
in general payments reported to CMS, 2019-2025
17 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.25 · 2021: $416 · 2022: $354 · 2023: $631 · 2024: $598 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.45 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $559.42 | 2021-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $530.54 | 2019-2025 | Unity, Ngenuity, Centurion |
| Genentech USA, INC. | $261.38 | 2022-2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $170.13 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $151.56 | 2023-2025 | Eylea Hd |
| Coherus Oncology, INC. | $148.82 | 2023 | |
| Bausch & Lomb Americas INC. | $147.87 | 2023 | Miebo, Vyzulta |
| Apellis Pharmaceuticals, INC. | $143.84 | 2023-2025 | Syfovre |
| Biogen, INC. | $136.20 | 2023-2024 | Byooviz |
| Genentech, INC. | $94.20 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.06 | 2021 | |
| Glaukos Corporation | $39.12 | 2023-2024 | Idose |
| Rayner Intraocular Lenses Limited | $33.74 | 2024 | Rayone Aspheric, Rayone Emv, Omidria |
| Sun Pharmaceutical Industries INC. | $26.93 | 2025 | |
| Ocular Therapeutix, INC. | $24.96 | 2024 | Dextenza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.67 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $20.53 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Yemm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.